HC Wainwright Reiterates Buy Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They presently have a $27.00 target price on the biopharmaceutical company’s stock.

MRNS has been the topic of a number of other research reports. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $3.00 price target (down previously from $24.00) on shares of Marinus Pharmaceuticals in a research note on Monday. StockNews.com cut Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 6th. Robert W. Baird reissued a “neutral” rating on shares of Marinus Pharmaceuticals in a research report on Tuesday. Oppenheimer restated a “market perform” rating and set a $9.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, March 7th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $28.00 price objective on shares of Marinus Pharmaceuticals in a report on Wednesday, April 10th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Marinus Pharmaceuticals presently has an average rating of “Hold” and an average target price of $18.21.

Marinus Pharmaceuticals Price Performance

MRNS stock opened at $1.44 on Tuesday. The stock has a market capitalization of $79.10 million, a price-to-earnings ratio of -0.55 and a beta of 0.91. The stock’s fifty day simple moving average is $8.72 and its 200-day simple moving average is $8.45. Marinus Pharmaceuticals has a 52-week low of $1.11 and a 52-week high of $11.26. The company has a quick ratio of 4.01, a current ratio of 4.07 and a debt-to-equity ratio of 5.68.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.10). The business had revenue of $7.19 million during the quarter, compared to analysts’ expectations of $7.78 million. Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative return on equity of 269.75%. During the same quarter last year, the firm earned ($0.76) EPS. Equities research analysts expect that Marinus Pharmaceuticals will post -2.43 EPS for the current year.

Institutional Trading of Marinus Pharmaceuticals

Large investors have recently bought and sold shares of the company. Nuveen Asset Management LLC grew its holdings in Marinus Pharmaceuticals by 1.1% during the 4th quarter. Nuveen Asset Management LLC now owns 139,752 shares of the biopharmaceutical company’s stock valued at $1,519,000 after purchasing an additional 1,475 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Marinus Pharmaceuticals by 2.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 95,047 shares of the biopharmaceutical company’s stock worth $889,000 after acquiring an additional 2,281 shares during the last quarter. Deutsche Bank AG lifted its stake in shares of Marinus Pharmaceuticals by 14.7% in the third quarter. Deutsche Bank AG now owns 25,961 shares of the biopharmaceutical company’s stock worth $209,000 after acquiring an additional 3,321 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Marinus Pharmaceuticals by 94.4% in the third quarter. Tower Research Capital LLC TRC now owns 7,541 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 3,661 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in Marinus Pharmaceuticals by 5.7% during the 3rd quarter. Rhumbline Advisers now owns 70,705 shares of the biopharmaceutical company’s stock valued at $569,000 after purchasing an additional 3,803 shares in the last quarter. Institutional investors and hedge funds own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.